Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/52—Cytokines; Lymphokines; Interferons
  • C07K14/53—Colony-stimulating factor [CSF]
  • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
  • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
  • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/10—Antimycotics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/18—Antivirals for RNA viruses for HIV
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/06—Antianaemics
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
  • C07K17/02—Peptides being immobilised on, or in, an organic carrier
  • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides

Definitions

• the present invention relates to a novel structure, a water-soluble polymer modified G-CSF conjugate of the formula (I) or a pharmaceutically acceptable salt thereof, and a process for the preparation thereof, and a compound of the formula (I) Or a pharmaceutical composition of a pharmaceutically acceptable salt thereof.
• G-CSF Granulocyte colony-stimulating factor
• monocytes and fibroblasts are produced by monocytes and fibroblasts and stimulates the formation of granulocyte colonies and stimulates neutrophils.
• G-CSF binds to target cell membrane receptors, mainly stimulates hematopoiesis in granulocyte lines, and also allows multi-functional hematopoietic stem cells to enter the cell cycle, promote proliferation, differentiation and maturation of myeloid hematopoietic cells, and drive the release of neutrophils to blood.
• the human G-CSF commonly used in the market is Neupogen and Neutrogin, and derivatives of human G-CSF, Neu-wp, derivatives or variant proteins of G-CSF, have also been reported in a large number of literatures [eg US 5,581,476, US 5,214,132, US 5,362,853, US 4,904,584 These variant proteins contain multiple amino acid substitutions in order to find a more stable, more active, and more clinically suitable G-CSF.
• Commercially available recombinant human G-CSF is poorly bioavailable in humans, has a short half-life, and is easily destroyed by proteases in the body. Therefore, frequent injections are required, and it is difficult to obtain a good clinical therapeutic effect.
• G-CSF or G-CSF variant proteins modified by polyethylene glycol have been disclosed in many documents, such as EP0335423, EP0401384, US5824778, US5985265, WO0044785, WO2001051510, US5824784, and the like.
• the conjugate obtained by modifying the N-terminus of G-CSF has the best in vitro and in vivo biological activity, but with an acylation reaction.
• the polyethylene glycol modified amino group has poor selectivity, so a mixture of polyethylene glycol modified at various positions is usually obtained, and separation and purification are required to obtain individual monomers, and the yield is low, which is difficult to industrially produce; in the patent US5824784 Direct modification of G-CSF with macromolecular polyethylene glycol aldehyde, by strictly controlling the pH of the reaction, and selectively modifying the N-terminus of G-CSF, a relatively specific N-terminal polyethylene glycol modified couple can be obtained. Linked, but it is undeniable that the selectivity of this reaction is achieved by the difference between the amino group of the side chain amino group and the N terminal amino group, which is quite difficult in preparation production and quality control.
• the present invention relates to a conjugate of the formula (I) or a pharmaceutically acceptable salt thereof.
• Water-soluble polymer-linking group-N-terminus-G' (I) wherein, the water-soluble polymer comprises polyethylene glycol, polypropylene glycol, polylactic acid, polymeric amino acid, etc., preferably polyethylene glycol, polyethylene glycol
• the molecular weight is selected from 2KD-100KD, preferably 5KD-40KD; the polyethylene glycol may be linear or branched;
• the linking group is formed by a specific reaction of a functional group at the end of the water-soluble polymer with a functional group introduced at the N-terminus of the protein G';
• G' is selected from natural G-CSF, recombinant G-CSF or a gene mutation product having G-CSF function, preferably a G-CSF derivative numbered SEQ ID NO: 1-10, more preferably a naturally occurring human source
• R is selected from a linear or branched fluorenyl group of CM, preferably a methyl group or an ethyl group, more preferably a methyl group;
• Ri, R 2 are independently selected from hydrogen or CM straight or branched fluorenyl groups, preferably hydrogen, methyl Or ethyl;
• X is selected from 0, S, NH, Mn or
• 1 is an integer selected from 1 to 20, preferably an integer of 1 to 10, more preferably an integer of 1 to 5; m is selected from an integer of 50 to 2,500, preferably an integer of 100 to 1000; n is an integer selected from 1 to 20, preferably An integer of 1-10, more preferably an integer of 1-5.
• the present invention relates to a conjugate of the above formula (I), (II) or a pharmaceutically acceptable salt thereof, which is characterized in that G' has a sequence of naturally occurring human G-CSF.
• the present invention relates to a conjugate of the above formula (I), (II) or a pharmaceutically acceptable salt thereof, which is characterized in that G is Met-G-CSF (SEQ ID NO: 1).
• the above conjugates of the formula (I) and (II) include:
• n is an integer selected from 400 to 500;
• the conjugate of the formula (I) and (II) of the present invention may form a salt with an acid selected from an organic acid or an inorganic acid, and the organic acid includes acetic acid, trifluoroacetic acid, propionic acid, butyric acid, Maleic acid or p-toluenesulfonic acid or a mixture thereof, preferably acetic acid or trifluoroacetic acid; the inorganic acid includes hydrochloric acid, sulfuric acid, phosphoric acid or methanesulfonic acid or a mixture thereof, preferably hydrochloric acid.
• the invention provides a method of preparing a conjugate of the formula (I), ( ⁇ ), comprising the steps of:
• R, , R 2 , G, X, 1, m, n are as defined above;
• Z is a thiol protecting group selected from the group consisting of: formyl, acetyl, propionyl, trityl or tert-butyl, preferably acetyl.
• the present invention relates to the use of the conjugate of the present invention or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating leukopenia, AIDS and other immunodeficiency diseases, bacterial infection diseases caused by radiotherapy or chemotherapy.
• the invention provides a pharmaceutical composition
• a pharmaceutical composition comprising a pharmaceutically effective amount of a conjugate of the invention, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
• the present invention relates to the use of the pharmaceutical composition for the preparation of a medicament for treating diseases such as leukopenia, AIDS and other immunodeficiency diseases, bacterial infections and the like due to radiotherapy and chemotherapy.
• the present invention discloses a novel class of polyethylene glycol modified G-CSF conjugates and novel preparation methods thereof, which have the following differences compared with conventional conjugates and methods:
• the specificity of the reaction at the N-terminus of the protein is ensured, because the protein obtained by modifying the N-terminus with a small molecule is easily separated and purified, and the specificity of the modification point is ensured;
• linking group due to the presence of a linking group, other functional groups are also likely to be added, such as the introduction of an imido group or an ester group, which provides a prerequisite for the release of G-CSF from the conjugate in vivo.
• the conjugate of the present invention or a pharmaceutically acceptable salt thereof has natural human G-CSF physiological activity, and has a longer in vivo circulating half-life and better granulocyte stimulating factor activity than G-CSF.
• R is selected from a linear or branched fluorenyl group of CM, preferably a methyl group or an ethyl group, more preferably a methyl group;
• Ri, R 2 are independently of each other selected from hydrogen or C M straight or branched fluorenyl, preferably hydrogen, methyl or ethyl;
• X is selected from 0, S, Li, 1 is selected from an integer from 1 to 20, preferably an integer from 1 to 10, more preferably an integer from 1 to 5; m is selected from an integer from 50 to 2500, preferably an integer from 100 to 1000; n is selected from an integer of 1-20, preferably an integer of 1-10, more preferably an integer of 1-5.
• G' is selected from natural G-CSF, recombinant G-CSF or gene mutation with G-CSF function
• the linking group can be linked to the amino group in G-CSF by various reaction methods (such as the reaction of various activated esters with an amino group), but considering the high selectivity of the reaction between the aldehyde group and the N-terminal amino group,
• a linking group is introduced by a reductive amination reaction of an aldehyde group with an N-terminal amino group in G-CSF.
• the reducing agent used is selected from various reducing agents well known to those skilled in the art, preferably sodium cyanoborohydride, sodium triacetoxyborohydride.
• the protecting group is trityl or tert-butyl
• the protecting group is removed using acidic conditions (such as trifluoroacetic acid, hydrochloric acid, methanesulfonic acid, etc.); when the protecting group is acetyl, propionyl, etc.
• acidic conditions such as trifluoroacetic acid, hydrochloric acid, methanesulfonic acid, etc.
• the protecting group is acetyl, propionyl, etc.
• the reaction is carried out by controlling the pH of the reaction, using a classical Michael addition, which has a good selectivity and can reach 99% or more.
• C M fluorenyl group means a linear or branched saturated aliphatic hydrocarbon group such as a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group or the like.
• human G-CSF is preferred, since there is no change in its internal sequence, which reduces the in vivo antigenicity of the protein and minimizes the formation of neutralizing antibodies in vivo. Improve the efficacy.
• Variant proteins of G-CSF and G-CSF can be obtained by methods known in the literature using conventional gene expression methods, including but not limited to Met-G-CSF, Trp-G-CSF, Asp-G-CSF, Glu-G. -CSF, preferably Met-G-CSF derived from E. coli expression (see SEQ ID NO: 1 for the sequence).
• the compounds obtained in the present invention are usually administered in dosage units.
• the dosage unit can be better described as a pharmaceutical composition obtained by mixing the active compound with a pharmaceutical excipient.
• the conjugate of the formula (I), ( ⁇ ) or a pharmaceutically acceptable salt thereof is an active compound.
• the pharmaceutical composition provided by the invention can be used as a adjuvant therapy for cancer patients undergoing chemotherapy or radiotherapy and bone marrow transplantation to prevent infection due to decreased immunity in vivo; and can also be used for treatment of patients with chronic or relative leukopenia It can also be used for the treatment of patients with acute myeloid leukemia, AIDS or other deficient diseases; it can also be used for antifungal treatment, especially for systemic or invasive Candida infections.
• the dose of the conjugate of the formula (I), (II) or a pharmaceutically acceptable salt thereof is from 5 to 500 ug/kg, wherein "ug” means a conjugate of the formula (I), (II) or A unit of measurement for a pharmaceutically acceptable salt, "kg” refers to a unit of measurement for the weight of a mammal.
• ug means a conjugate of the formula (I), (II) or A unit of measurement for a pharmaceutically acceptable salt
• “kg” refers to a unit of measurement for the weight of a mammal.
• the conjugate obtained by the present invention or a pharmaceutically acceptable salt thereof can be prepared in various unit forms by mixing with a conventional pharmaceutical carrier, and administered in various manners such as subcutaneous, intramuscular, and intravenous.
• Figure 1 MALDI-TOF-TOF chart of Compound 1 of the present invention
• Figure 2 MALDI-TOF-TOF chart of Compound 2 of the present invention
• Figure 3 PEG-G-CSF, G-CSF to cyclophosphamide treated mice The influence of peripheral blood leukocyte counts;
• Figure 4 Effect of PEG-G-CSF, G-CSF on the peripheral blood red blood cell count of cyclophosphamide-treated mice;
• Figure 5 Effect of PEG-G-CSF and G-CSF on peripheral blood platelet counts in cyclophosphamide-treated mice
• Embodiment 1 In order to explain the present invention in more detail, the following examples are given. However, the scope of the invention is not limited thereto. Embodiment 1
• the Met-G-CSF stock solution was dialyzed and converted to 0.1 M acetic acid/sodium acetate solution, and 140 ml was obtained, which contained about 40 mg of protein.
• a small molecule aldehyde (7.0 mg) was dissolved in acetonitrile (300 ml), added to a protein solution, and sodium cyanoborohydride (176 mg) was added thereto, and the mixture was stirred at room temperature for 3 hours.
• the column was packed with SP Sepharose H.P, 1.6 cm x 12 cm, volume about 24 ml, flow rate: 4 ml/min,
• Pretreatment of the column first wash 5 times volume with 0.5M NaOH solution;
• the volume was washed 5 times with 20 mM HAc/NaAc, pH 4.0 to equilibration.
• Loading directly pump the desalted sample into the column with a pump;
• the salt gradient was further set: 0 to 50%, 50 min, 4 ml/min, and impurities, products, and unreacted proteins were sequentially eluted and collected.
• mPEG-Met-G-CSF 39KD is the preparation of compound 1 injection Sodium acetate: 0.12 g
• PEG-G-CSF refers to Compound 1 of the present invention. 1 Test purpose
• CX cyclophosphamide
• Kunming mice were purchased from the Shanghai Experimental Animal Center of the Chinese Academy of Sciences, weighing 18-22 g, $, and the number of animals in each group: 10.
• PEG-G-CSF single subcutaneous injection increased the peripheral blood leukocyte count of mice treated with cyclophosphamide, and the white blood cell count returned to normal level when administered at 0.5 mg/kg; 1.0 mg/kg when administered, peripheral The white blood cell count was even higher than normal (PO.01 vs. control, Figure 3).

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Immunology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Molecular Biology (AREA)
• Biochemistry (AREA)
• Oncology (AREA)
• Biophysics (AREA)
• Genetics & Genomics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Hematology (AREA)
• Communicable Diseases (AREA)
• Toxicology (AREA)
• Diabetes (AREA)
• Zoology (AREA)
• Gastroenterology & Hepatology (AREA)
• Virology (AREA)
• Epidemiology (AREA)
• Transplantation (AREA)
• AIDS & HIV (AREA)
• Tropical Medicine & Parasitology (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Peptides Or Proteins (AREA)

Priority Applications (5)

Applications Claiming Priority (1)

Publications (1)

Family

ID=40985048

Family Applications (1)

Country Status (5)

Families Citing this family (4)

Citations (14)

Family Cites Families (1)

• 2008
  • 2008-02-18 US US12/918,280 patent/US8629104B2/en active Active
  • 2008-02-18 ES ES08706693.2T patent/ES2523030T3/es active Active
  • 2008-02-18 EP EP08706693.2A patent/EP2248832B1/en not_active Not-in-force
  • 2008-02-18 JP JP2010546197A patent/JP5225393B2/ja not_active Expired - Fee Related
  • 2008-02-18 WO PCT/CN2008/070320 patent/WO2009103199A1/zh not_active Ceased

Patent Citations (16)

Non-Patent Citations (6)

Also Published As

Similar Documents

Legal Events